87 related articles for article (PubMed ID: 28742202)
1. Does the age affect the efficacy of angiogenesis inhibitors in ovarian cancer? A meta-analysis of randomized controlled trials.
Miao H; Miao CX; Han J; Li N
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(13):3047-3053. PubMed ID: 28742202
[TBL] [Abstract][Full Text] [Related]
2. The role of angiogenesis inhibitors in the treatment of elderly patients with advanced non-small-cell lung cancer: A meta-analysis of eleven randomized controlled trials.
Tian RH; Wu X; Liu X; Yang JW; Ji HL; Yan YJ
J Cancer Res Ther; 2016; 12(2):571-5. PubMed ID: 27461612
[TBL] [Abstract][Full Text] [Related]
3. The role of targeted agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials.
Wang CW; Fang XH
Eur Rev Med Pharmacol Sci; 2016 May; 20(9):1725-32. PubMed ID: 27212163
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials.
Wang H; Xu T; Zheng L; Li G
Int J Gynecol Cancer; 2018 Jun; 28(5):903-914. PubMed ID: 29561301
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
Guo C; Yan C; Qu L; Du R; Lin J
Arch Gynecol Obstet; 2021 Feb; 303(2):285-311. PubMed ID: 33222040
[TBL] [Abstract][Full Text] [Related]
6. The role of angiogenesis inhibitors re-challenge in colorectal cancer previously treated with bevacizumab: a meta-analysis of randomized controlled trials.
Xiong YX; Ren L; Wang ZQ; Huang XW; Zhou YJ
Eur Rev Med Pharmacol Sci; 2017 Apr; 21(7):1489-1494. PubMed ID: 28429359
[TBL] [Abstract][Full Text] [Related]
7. Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis.
Feng Y; Huang H; Wan T; Zhang C; Tong C; Liu J
Adv Ther; 2019 Dec; 36(12):3368-3380. PubMed ID: 31599396
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials.
Jiang Y; Sun X; Kong B; Jiang J
Medicine (Baltimore); 2018 Aug; 97(34):e11920. PubMed ID: 30142803
[TBL] [Abstract][Full Text] [Related]
9. A pooled analysis of molecularly targeted agents for treatment of metastatic oesophago-gastric cancer in elderly patients.
Lv H; Zhou QH; Zhong DS
Arch Med Sci; 2020; 16(2):253-259. PubMed ID: 32190134
[TBL] [Abstract][Full Text] [Related]
10. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials.
Li J; Zhou L; Chen X; Ba Y
Clin Transl Oncol; 2015 Sep; 17(9):673-83. PubMed ID: 25990506
[TBL] [Abstract][Full Text] [Related]
11. The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced NSCLC: a meta-analysis of randomized controlled trials.
Zhang J; Liu J; Chen H; Wu W; Li X; Wu Y; Zhang K; Gu L
Onco Targets Ther; 2015; 8():2375-82. PubMed ID: 26366091
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of targeted agents in the treatment of elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Chen J; Chen J; Wu X; Shi T; Kang M
Onco Targets Ther; 2016; 9():4797-803. PubMed ID: 27536143
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis.
Li J; Li S; Chen R; Yu H; Lu X
J Ovarian Res; 2015 Aug; 8():54. PubMed ID: 26242216
[TBL] [Abstract][Full Text] [Related]
14. Dose age affect the efficacy of molecular targeted agents in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis.
Du J; Mao Y; Liu M; Tie Y; Huang H; Zhao J; Xiang Z; Luo D
Oncotarget; 2017 Nov; 8(60):102413-102419. PubMed ID: 29254256
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials.
Li X; Zhu S; Hong C; Cai H
Curr Med Res Opin; 2016; 32(3):555-62. PubMed ID: 26652645
[TBL] [Abstract][Full Text] [Related]
16. Adverse events risk associated with angiogenesis inhibitors addition to therapy in ovarian cancer: a meta-analysis of randomized controlled trials.
Liang XJ; Shen J
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2701-9. PubMed ID: 27383326
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials.
Ye Q; Chen HL
Arch Gynecol Obstet; 2013 Sep; 288(3):655-66. PubMed ID: 23543268
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of molecular targetted agents in the treatment of elderly patients with metastatic colorectal cancer: does the age matter?
Zhao C; Li S; Liu Q
J Chemother; 2016 Aug; 28(4):321-7. PubMed ID: 26239366
[TBL] [Abstract][Full Text] [Related]
20. Systematic evaluation of bevacizumab in recurrent ovarian cancer treatment.
Ding SS; Li L; Yu CX
J BUON; 2014; 19(4):965-72. PubMed ID: 25536603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
